1. Home
  2. POET vs ANAB Comparison

POET vs ANAB Comparison

Compare POET & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo POET Technologies Inc.

POET

POET Technologies Inc.

HOLD

Current Price

$7.66

Market Cap

1.5B

Sector

Technology

ML Signal

HOLD

ANAB

AnaptysBio Inc.

HOLD

Current Price

$52.89

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
POET
ANAB
Founded
1972
2005
Country
Canada
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.3B
IPO Year
2008
2015

Fundamental Metrics

Financial Performance
Metric
POET
ANAB
Price
$7.66
$52.89
Analyst Decision
Buy
Analyst Count
0
12
Target Price
N/A
$71.67
AVG Volume (30 Days)
15.4M
640.4K
Earning Date
08-12-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
91.02
EPS
N/A
N/A
Revenue
N/A
$234,603,000.00
Revenue This Year
$848.96
N/A
Revenue Next Year
$700.00
$52.14
P/E Ratio
N/A
N/A
Revenue Growth
N/A
157.01
52 Week Low
$3.87
$17.11
52 Week High
$20.65
$73.30

Technical Indicators

Market Signals
Indicator
POET
ANAB
Relative Strength Index (RSI) 39.45 41.31
Support Level $6.58 $52.32
Resistance Level $7.74 $57.70
Average True Range (ATR) 0.64 4.99
MACD 0.00 -1.59
Stochastic Oscillator 16.81 14.95

Price Performance

Historical Comparison
POET
ANAB

About POET POET Technologies Inc.

POET Technologies Inc is a design and development company offering high-speed optical engines, light source products, and custom optical modules to the artificial intelligence systems market and hyperscale data centers. Its integration solutions are based on the POET Optical Interposer, a novel, patented platform that allows the seamless integration of electronic and photonic devices into a single chip using wafer-level semiconductor manufacturing techniques. POET's Optical Interposer platform also solves device integration challenges across a broad range of communication, computing, and sensing applications. The company operates geographically in the United States, Canada, Singapore and China.

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Share on Social Networks: